Charles River Laboratories to Acquire K.F. (Cambodia) and PathoQuest SAS

Reuters01-13

Charles River Laboratories to Acquire <a href="https://laohu8.com/S/TKKD.SI">K</a>.F. (Cambodia) and PathoQuest SAS

Charles River Laboratories is moving forward with two planned acquisitions to strengthen its business operations. The company has signed an agreement to acquire K.F. (Cambodia) Ltd., a key supplier of non-human primates (NHPs) for its Discovery and Safety Assessment segment. This acquisition is expected to enhance supply chain security, provide significant cost savings, and improve operating margins. Additionally, Charles River Laboratories has exercised its option to acquire the remaining 79% equity stake in PathoQuest SAS, a Paris-based provider of next generation sequencing solutions for biopharmaceutical manufacturing quality-control testing. The PathoQuest acquisition aims to bolster Charles River’s biologics testing capabilities with innovative, rapid in vitro testing methods that support the replacement of animal use in viral safety workflows and accelerate clients’ quality-control timelines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112549794) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603526207?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603526207","market":"fut","top_or_hot":-1,"title":"Charles River Laboratories to Acquire K.F. (Cambodia) and PathoQuest SAS","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Charles River Laboratories to Acquire <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>.F. (Cambodia) and PathoQuest SAS\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Charles River Laboratories is moving forward with two planned acquisitions to strengthen its business operations. The company has signed an agreement to acquire K.F. (Cambodia) Ltd., a key supplier of non-human primates (NHPs) for its Discovery and Safety Assessment segment. This acquisition is expected to enhance supply chain security, provide significant cost savings, and improve operating margins. Additionally, Charles River Laboratories has exercised its option to acquire the remaining 79% equity stake in PathoQuest SAS, a Paris-based provider of next generation sequencing solutions for biopharmaceutical manufacturing quality-control testing. The PathoQuest acquisition aims to bolster Charles River’s biologics testing capabilities with innovative, rapid in vitro testing methods that support the replacement of animal use in viral safety workflows and accelerate clients’ quality-control timelines.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112549794) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Charles River Laboratories to Acquire K.F. (Cambodia) and PathoQuest SAS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCharles River Laboratories to Acquire K.F. (Cambodia) and PathoQuest SAS\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 05:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Charles River Laboratories to Acquire <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>.F. (Cambodia) and PathoQuest SAS\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Charles River Laboratories is moving forward with two planned acquisitions to strengthen its business operations. The company has signed an agreement to acquire K.F. (Cambodia) Ltd., a key supplier of non-human primates (NHPs) for its Discovery and Safety Assessment segment. This acquisition is expected to enhance supply chain security, provide significant cost savings, and improve operating margins. Additionally, Charles River Laboratories has exercised its option to acquire the remaining 79% equity stake in PathoQuest SAS, a Paris-based provider of next generation sequencing solutions for biopharmaceutical manufacturing quality-control testing. The PathoQuest acquisition aims to bolster Charles River’s biologics testing capabilities with innovative, rapid in vitro testing methods that support the replacement of animal use in viral safety workflows and accelerate clients’ quality-control timelines.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112549794) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0390134368.USD","symbol_name":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7zTLLr:1","article_id":"2603526207","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603526207","pubTimestamp":1768253448,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Charles River Laboratories is moving forward with two planned acquisitions to strengthen its business operations. The company has signed an agreement to acquire K.F.  Ltd., a key supplier of non-human primates  for its Discovery and Safety Assessment segment. This acquisition is expected to enhance supply chain security, provide significant cost savings, and improve operating margins. Additionally, Charles River Laboratories has exercised its option to acquire the remaining 79% equity stake in PathoQuest SAS, a Paris-based provider of next generation sequencing solutions for biopharmaceutical manufacturing quality-control testing. The PathoQuest acquisition aims to bolster Charles River’s biologics testing capabilities with innovative, rapid in vitro testing methods that support the replacement of animal use in viral safety workflows and accelerate clients’ quality-control timelines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4530":"医药外包概念","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4121":"生命科学工具和服务","BK4585":"ETF&股票定投概念","CRL":"查尔斯河","BK4588":"碎股"},"translate_title":"查尔斯河实验室将收购K.F.（柬埔寨）和PathoQuest SAS","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":0.9},"content_text":"Charles River Laboratories to Acquire K.F. (Cambodia) and PathoQuest SAS\n    \n\n        Charles River Laboratories is moving forward with two planned acquisitions to strengthen its business operations. The company has signed an agreement to acquire K.F. (Cambodia) Ltd., a key supplier of non-human primates (NHPs) for its Discovery and Safety Assessment segment. This acquisition is expected to enhance supply chain security, provide significant cost savings, and improve operating margins. Additionally, Charles River Laboratories has exercised its option to acquire the remaining 79% equity stake in PathoQuest SAS, a Paris-based provider of next generation sequencing solutions for biopharmaceutical manufacturing quality-control testing. The PathoQuest acquisition aims to bolster Charles River’s biologics testing capabilities with innovative, rapid in vitro testing methods that support the replacement of animal use in viral safety workflows and accelerate clients’ quality-control timelines.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112549794) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603526207","isCrawlerRequest":true}